Raith W, Gamillscheg A, Heinzl B, Nagel B H P, Koestenberger M, Beitzke A
Universitätsklinik für Kinder- und Jugendheitkunde, Abteilung für Pädiatrische Kardiologie, Graz, Osterreich.
Klin Padiatr. 2009 Mar-Apr;221(2):83-8. doi: 10.1055/s-0028-1119372. Epub 2009 Mar 4.
Kawasaki syndrome was described for the first time by Tomisaku Kawasaki in 1967. This disease is characterized by panvasculitis of the small blood vessels of the skin, the mucous membranes, the internal organs and the coronary vessels and has an unclear etiology. Inflammatory changes in the coronary vessels or late diagnosis are prognostically unfavorable for the early and late mortality.
Since two of our patients with Kawasaki syndrome with a short, severe course died despite receiving state-of-the-art treatment, we retrospectively evaluated the medical records of all the children we have treated since October 1978 with regard to the symptoms at the time of diagnosis, intervals between the onset of the disease, diagnosis, beginning of treatment and the result of treatment.
Kawasaki syndrome was diagnosed in 80 patients in the period from October 1978 to October 2007. The patients were grouped according to the phase of the disease and the number of organs affected at the time of diagnosis (Asai-Score) as well as the treatment carried out. The time of the first presentation for diagnosis by the pediatrician was also considered.
This is a single-institution retrospective analysis of the medical records, echocardiography and angiography findings of all patients. In view of the change of therapy in that year, patients who had been diagnosed before 1987 were compared with those diagnosed after 1987.
Before 1987, the patients were treated solely with high doses of acetylsalicylic acid (50-100 mg/kg/day p.o. over two to four weeks). Out of a total of 36 patients, 13 showed involvement of the coronary arteries that persisted in seven patients despite treatment. After 1987, all patients received intravenous immunoglobulins (4 x 0.5 g/kg/day resp. 1 x 2 g/kg i.v. over 12 hours). In 18 out of 44 patients, the coronary arteries were affected at the time of diagnosis, but this did not persist in any of the patients. One child died in each group. Comparing the two treatment groups also revealed that a physician was consulted for the first time after a very much shorter duration of the disease in the second treatment period (3+/-1.8 vs. 6+/-2.4 days after onset of the illness) and that a pediatrician was consulted much more frequently as the first port of call. This was reflected in a significantly earlier beginning of treatment and a simultaneous significantly lower Asai score.
The retrospective evaluation of all medical records did not reveal any plausible explanation for the fatal course of the disease in one child in each of the two treatment periods. Besides the combination therapy with intravenous immunoglobulin and oral administration of acetylsalicylic acid, the greater age and the earlier commencement of treatment appeared to be salient factors resulting in complete cure of the disease in the surviving patients in the second period of treatment.
川崎病于1967年由川崎富作首次描述。该病以皮肤、黏膜、内脏及冠状动脉的小血管全层血管炎为特征,病因不明。冠状动脉的炎症变化或诊断延迟对早、晚期死亡率的预后不利。
由于我们两名病程短且严重的川崎病患者尽管接受了先进治疗仍死亡,我们回顾性评估了自1978年10月以来我们所治疗的所有儿童的病历,涉及诊断时的症状、疾病发作、诊断、开始治疗之间的间隔以及治疗结果。
1978年10月至2007年10月期间,80例患者被诊断为川崎病。根据疾病阶段、诊断时受累器官数量(浅井评分)以及所进行的治疗对患者进行分组。还考虑了儿科医生首次进行诊断的时间。
这是对所有患者的病历、超声心动图和血管造影结果进行的单机构回顾性分析。鉴于当年治疗方法的变化,将1987年前诊断的患者与1987年后诊断的患者进行比较。
1987年前,患者仅接受高剂量阿司匹林治疗(口服50 - 100mg/kg/天,持续两至四周)。在总共36例患者中,13例显示冠状动脉受累,尽管治疗仍有7例持续存在。1987年后,所有患者接受静脉注射免疫球蛋白(4×0.5g/kg/天或1×2g/kg静脉注射,持续12小时)。44例患者中有18例在诊断时冠状动脉受累,但在任何患者中均未持续存在。每组各有一名儿童死亡。比较两个治疗组还发现,在第二个治疗期,疾病持续时间短得多时(发病后3±1.8天对6±2.4天)首次咨询医生,且儿科医生作为首选咨询的频率更高。这体现在治疗开始明显更早且同时浅井评分显著更低。
对所有病历的回顾性评估未发现两个治疗期各有一名儿童出现致命病程的合理原因。除了静脉注射免疫球蛋白和口服阿司匹林的联合治疗外,年龄较大和治疗开始较早似乎是导致第二个治疗期存活患者完全治愈疾病的显著因素。